August 25, 2025

AACR 2025: AI-Driven Analysis of Digital Pathology Images May Improve Sarcoma Subtyping Among Pediatric Patients

Researchers explored the potential of a novel artificial intelligence (AI)-based model to classify sarcomas among pediatric patients using digital pathology images alone, according to findings present...

The ASCO Post

August 22, 2025

Protease Activator Approved by the FDA for Diffuse Midline Glioma

This represents the first FDA approval of a systemic therapy for H3 K27M–mutant diffuse midline glioma.

The ASCO Post

May 05, 2023

Limited Surgery Plus Proton Therapy in Pediatric and Adolescent Patients With Craniopharyngioma

In a phase II trial (RT2CR) reported in The Lancet Oncology, Thomas E. Merchant, DO, and colleagues found that limited surgery plus proton therapy was associated with a high rate of disease control an...

The ASCO Post

March 28, 2024

Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma

On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior...

The ASCO Post

February 08, 2023

Higher Rate of Clonal Hematopoiesis in Pediatric Cancer Survivors May Be Linked With Treatment-Induced STAT3 Gene Mutations and Risk of Adverse Long-Term Outcomes

A large study by researchers at St. Jude Children’s Research Hospital has identified a higher rate of clonal hematopoiesis as well as significant enrichment in treatment-related STAT3 gene mutations i...

The ASCO Post

June 25, 2024

Tovorafenib in Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

U.S. FDA accelerates approval for tovorafenib (Ojemda) to treat pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation, providing a promising therapeutic option for these patients. Learn more at (source).

The ASCO Post

August 13, 2024

FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park.

The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.

Roswell Park Comprehensive Cancer Center

May 23, 2024

Clinical Trial Mounts Two-Pronged Attack Against Relapsed/Refractory Pediatric Sarcomas

In recent years investigators have launched a growing number of clinical trials evaluating the efficacy of combining chemotherapy and immunotherapy in a two-pronged attack against cancer.

Roswell Park Comprehensive Cancer Center

February 06, 2025

Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL

A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-c...

The ASCO Post